Does Blood Flow to a Mass Mean Cancer?

Blood flow to a mass does not, on its own, mean cancer. Many benign growths, inflamed tissues, and even normal anatomical structures show robust blood flow on imaging, and some cancers show very little. Doctors look at blood flow as one piece of a much larger diagnostic puzzle, but the presence or absence of vascularity rarely settles the question by itself. The pattern of that blood flow, the organ involved, and a handful of other imaging features all matter far more than a simple yes-or-no reading of whether blood is reaching a lump.

Why Cancers Often Have Increased Blood Flow

Cancers need oxygen and nutrients to grow, and once a tumor reaches a certain size, the existing blood supply can’t keep up. The interior of the growing mass becomes oxygen-starved, and that low-oxygen environment triggers cells to ramp up production of signaling molecules that recruit new blood vessels. The most studied of these signals is vascular endothelial growth factor, or VEGF. Research on tumor cells has shown that when they’re deprived of oxygen, VEGF production goes up, and when oxygen is restored, it drops back down.¹ Even normal endothelial cells (the cells lining blood vessels) can be pushed to express VEGF when oxygen levels fall, through a specific genetic switch called hypoxia-inducible factor.²

This process of building new blood vessels is called angiogenesis, and it’s a hallmark of many cancers. But the vessels tumors build are not like the orderly plumbing in healthy tissue. Tumor blood vessels tend to be chaotic, leaky, and irregularly branched. Researchers have identified at least six structurally distinct types of abnormal vessels in tumors, formed through different mechanisms.³ That structural abnormality is actually one of the things that helps radiologists distinguish malignant blood flow from benign blood flow on imaging, though in practice the distinction is far from clean.

Benign Masses That Show Plenty of Blood Flow

If increased blood flow equaled cancer, diagnosis would be straightforward. It isn’t, because plenty of non-cancerous conditions are well-supplied with blood.

In the liver, two of the most common benign masses are hemangiomas and focal nodular hyperplasia (FNH). Hemangiomas are tangles of blood vessels, so by definition they’re full of blood flow. FNH lesions are so vascular that they show a characteristic “spoked wheel” pattern of arteries radiating from a central scar. On contrast-enhanced ultrasound, nearly all FNH lesions fill rapidly from the center outward.⁴ These lesions can look alarming on initial imaging precisely because of how vascular they are, but they’re benign and almost never need treatment.

In the breast, fibroadenomas are among the most common benign lumps, especially in younger women. Some fibroadenomas show detectable blood flow on Doppler ultrasound. One study comparing fibroadenomas with breast cancers found blood flow in about a third of fibroadenomas, though cancers were more likely to have it, with detectable flow in roughly three-quarters of malignant masses.⁵ So a breast lump with visible blood flow could be either one.

In the kidney, angiomyolipomas are the most common benign renal tumor. Despite being benign, they’re composed partly of blood vessels and can appear highly vascular on imaging. Their identifying feature is the presence of fat within the mass, not the degree of blood flow.

And then there’s inflammation. Tendinitis, bursitis, abscesses, and even symptomatic cysts like wrist ganglia can show dramatic increases in blood flow on Doppler ultrasound. In one study looking at soft-tissue problems, power Doppler detected hyperemia (excess blood flow) in the symptomatic area in nearly every case, ranging from a diffuse tissue blush to large individual vessels.⁶ Inflammation is the body’s natural healing response, and part of that response involves flooding the area with blood. A mass that’s inflamed or infected can light up on imaging in a way that looks dramatic but has nothing to do with cancer.⁷

What Imaging Actually Looks For

When a radiologist evaluates blood flow to a mass, the question is rarely “is there flow or not?” It’s about the characteristics of that flow: where the vessels are, how they’re arranged, and how quickly blood moves through them.

Ultrasound with Doppler is often the first tool used. It can map blood vessels within and around a mass, showing whether vessels penetrate into the center of the lesion or stay at the edges. In breast masses, the location of vessels makes a real difference. One study found that vessels penetrating into the interior of a lump pointed toward cancer with about 95% specificity, while benign fibroadenomas overwhelmingly had either no detectable vessels or only vessels at the periphery.⁸

Doppler can also measure how resistant the blood vessels are to flow, captured in a number called the resistive index. Malignant breast masses tend to have higher resistance than benign ones. One study found that about 80% of breast cancers had a resistive index above 0.7, compared to a lower average in benign masses.⁹ A more recent study of breast masses confirmed that resistance and pulsatility indices had good diagnostic value for predicting malignancy, with area-under-the-curve values above 0.85 for both metrics.¹⁰

That said, the overlap between benign and malignant readings is substantial. Blood flow analysis on its own is not specific enough to confidently diagnose or rule out cancer in most situations. One study of soft-tissue tumors found that an organized vascular pattern on color Doppler was a good indicator that a tumor was benign, but that pattern only showed up in less than a third of cases.¹¹ For the majority of masses, flow characteristics alone couldn’t reliably separate the benign from the malignant.

The Thyroid Exception

The thyroid is an especially instructive example of why blood flow alone is unreliable. A meta-analysis of thyroid nodules found no significant difference in overall vascular flow rates between malignant and benign nodules. About a third of thyroid cancers had no detectable blood flow at all, while half showed internal vascularity.¹² Internal flow was more common in cancers, but the difference wasn’t statistically significant.

Meanwhile, some entirely benign thyroid nodules can be extremely vascular. Research has shown that larger benign thyroid tumors tend to develop more internal blood flow as they grow, simply because bigger tissue needs more supply.¹³ In nodules smaller than two centimeters, increased internal vascularity was more useful as a predictor, with specificity around 86%. But for the thyroid overall, blood flow is not a reliable way to tell benign from malignant. This is part of why thyroid nodule evaluation relies heavily on other ultrasound features, and ultimately on fine-needle aspiration biopsy, rather than on Doppler blood flow.

Cancers That Hide Behind Low Blood Flow

The flip side of “blood flow doesn’t mean cancer” is “lack of blood flow doesn’t mean safe.” Some cancers are notoriously hypovascular, meaning they don’t attract much new blood supply relative to the surrounding tissue. Pancreatic ductal adenocarcinoma is the classic example. These tumors are often surrounded by dense scar-like tissue that limits their blood supply. In about 5 to 11% of cases, the cancer blends in with surrounding pancreas tissue on imaging because it has a similar level of blood flow and contrast uptake, making it effectively invisible on standard scans.¹⁴ This is most common with smaller tumors, under two centimeters.

Some aggressive melanoma cells take the concept further. Rather than relying on normal angiogenesis, certain highly aggressive cancer cells can form their own blood-carrying channels without the involvement of blood vessel cells at all. This phenomenon, called vasculogenic mimicry, involves the tumor cells themselves creating patterned channels that can transport fluid and even connect to the body’s existing blood supply.¹⁵ ¹⁶ These makeshift channels don’t always show up the same way as conventional blood vessels on imaging, which means a cancer using this strategy might appear less vascular than expected while still growing aggressively.

Advanced Imaging Gets Closer to an Answer

Because simple Doppler has clear limitations, more sophisticated imaging approaches try to characterize blood flow with greater precision. Dynamic contrast-enhanced MRI involves injecting a contrast agent and then watching how quickly it washes into and out of a mass over time. This technique captures information about how leaky the vessels are and how dense the microvasculature is, which helps distinguish benign from malignant tissue.¹⁷ In head and neck cancer patients being monitored after treatment, combining contrast-enhanced MRI parameters achieved an area under the curve of 0.97 for telling cancer recurrence apart from benign post-treatment changes, a near-perfect result.¹⁸

Contrast-enhanced ultrasound (CEUS) takes a similar approach but using microbubble contrast agents with standard ultrasound equipment. The microbubbles stay within blood vessels, allowing real-time visualization of how blood flows through a mass. This has proven especially useful for liver masses, where the filling pattern on CEUS can help distinguish FNH from hepatic adenoma. FNH characteristically shows centrifugal filling (from the center outward), while adenomas tend to fill from the edges inward.⁴ CEUS also helps identify the peripheral nodular enhancement pattern typical of hemangiomas.¹⁹

Even newer approaches are pushing the resolution further. Super-resolution ultrasound builds on contrast-enhanced ultrasound to reconstruct detailed maps of tiny blood vessels within tissue, potentially revealing structural differences invisible to conventional techniques.²⁰ And artificial intelligence models are being trained to analyze vascular patterns alongside texture, shape, and clinical variables. One model for classifying lung nodules found that incorporating the count of blood vessels around a nodule as a feature significantly improved its ability to distinguish malignant from benign growths, with the perinodular vessel count consistently ranking among the most important predictive features.²¹

Why Biopsy Still Wins

With all these advances, imaging still can’t definitively diagnose most masses by blood flow or vascularity alone. The overlap between benign and malignant patterns is simply too large. A comprehensive review of color Doppler in breast lesions concluded that vessel count, flow speed, and resistance values did not permit clear differentiation between malignant and benign tumors, though they did correlate with how aggressive a cancer was if it turned out to be malignant.²²

For small liver nodules in patients at risk for hepatocellular carcinoma, imaging looks for a specific combination of arterial-phase enhancement followed by washout. But even with both CT and MRI available, the two techniques disagreed in about 28% of patients in one study, and nearly a third of small liver cancers showed no washout on either scan. In those ambiguous cases, biopsy was what provided the accurate initial diagnosis.²³

This is the reality of diagnostic imaging: blood flow provides clues, sometimes very strong ones, but the final answer almost always comes from looking at cells under a microscope. If your doctor has noted blood flow to a mass on an ultrasound or CT, it means the finding needs to be interpreted in context, not that cancer has been diagnosed.

How Anti-Angiogenesis Drugs Fit Into Treatment

The relationship between blood flow and cancer has driven an entire category of cancer drugs. Anti-angiogenic therapies aim to cut off a tumor’s blood supply by blocking the VEGF signaling pathway, either with antibodies that neutralize VEGF itself or with drugs that block the receptors on blood vessel cells.²⁴ The logic is straightforward: if a tumor needs new blood vessels to grow, starving it of those vessels should slow or stop growth.

These drugs have become part of standard treatment for several cancers. But their story also illustrates the complexity of tumor vascularity. Tumors can develop resistance to anti-VEGF therapy through multiple routes, including switching to alternative blood-vessel-growth signals, or relying on those tumor-cell-formed channels described earlier. Not all tumor vessel types depend on VEGF, and the ones that don’t will keep functioning even when VEGF-targeted drugs are given. This is why researchers have argued for targeting specific vessel subtypes rather than treating all tumor vessels as the same.³ It also explains why anti-angiogenic drugs often slow tumor progression rather than eliminating tumors entirely.

For patients, the practical takeaway is that tumor blood supply is a treatment target, not just a diagnostic feature. The same vascularity that makes a mass look concerning on imaging is also a potential vulnerability. But shutting it down completely has turned out to be harder than it seemed when the first anti-angiogenic drugs were developed, in part because tumors are surprisingly resourceful at finding alternative ways to feed themselves.²⁵

What to Ask Your Doctor

If you’ve had imaging that mentions blood flow to a mass and you’re trying to make sense of it, a few questions can help clarify what the finding actually means in your case. Ask whether the blood flow pattern is typical for a particular kind of lesion, benign or malignant. Ask whether additional imaging with contrast could help narrow things down. And ask whether biopsy is recommended, or whether the combination of features is reassuring enough to monitor the mass over time instead.

The anxiety that comes with seeing “increased vascularity” or “blood flow detected” on a report is understandable. But a mass with blood flow is not a cancer diagnosis. It’s a description of what the tissue looks like on imaging, and interpreting it correctly requires weighing it against everything else: the organ involved, the size and shape of the mass, your age and risk factors, and the specific pattern of that blood flow. In many cases, what looks worrisome at first glance turns out to be a hemangioma, a fibroadenoma, an inflamed tendon, or one of the many other benign things the body produces that happen to attract a healthy blood supply.